Skip to content
Screener

Revolution Medicines, Inc. RVMD Q2 2026 earnings

Reported August 5, 2026 · After market close

EPS-$3.06Miss by $1.02
Revenue estimate$1.8M
EPS estimate-$2.04

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$13.4M
EPS estimate-$2.44

Financials

Q2 2026

Income statement

See full
Operating income-$505.1M-90.8%
Net income-$644.4M-160%
EPS (diluted)-$3.06-134%

Balance sheet

See full
Cash & equivalents$815.4M+103%
Total debt$154.5M+16.3%
Total equity$2.6B+39.7%
Total assets$4.3B+77.9%

Cash flow

See full
Operating cash flow-$387.3M-74.7%
CapEx$2.3M-69.3%
Free cash flow-$389.6M-70.0%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$46.18B+549%
Enterprise value$45.52B+565%

Returns & leverage

See full
Return on equity-79.1%+182pp
Debt / equity0.1×0.0×
Current ratio11.4×-0.4×

FAQ

When did Revolution Medicines, Inc. report Q2 2026 earnings?
Revolution Medicines, Inc. (RVMD) reported Q2 2026 earnings on August 5, 2026 after market close.
What were Revolution Medicines, Inc.'s Q2 2026 revenue and EPS?
Revolution Medicines, Inc. reported eps of $-3.06 for Q2 2026.
Did Revolution Medicines, Inc. beat estimates in Q2 2026?
EPS missed the consensus estimate of $-2.04 by $1.02.
How did Revolution Medicines, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 133.6% from $-1.31.
Where can I find Revolution Medicines, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-335039) and the 10-Q periodic report (0001193125-26-335104) directly on SEC EDGAR. The filing index links above go to sec.gov.